Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

Related Articles by Review for PubMed (Select 19905037)

1.

The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda.

Marseille E, Kahn JG, Pitter C, Bunnell R, Epalatai W, Jawe E, Were W, Mermin J.

Appl Health Econ Health Policy. 2009;7(4):229-43. doi: 10.2165/11318740-000000000-00000.

2.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

3.

Darunavir: a review of its use in the management of HIV infection in adults.

McKeage K, Perry CM, Keam SJ.

Drugs. 2009;69(4):477-503. doi: 10.2165/00003495-200969040-00007. Review.

PMID:
19323590
4.

A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.

Mauskopf J, Annemans L, Hill AM, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:1-16. doi: 10.2165/11587410-000000000-00000. Review.

PMID:
21182340
5.

Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence.

Creese A, Floyd K, Alban A, Guinness L.

Lancet. 2002 May 11;359(9318):1635-43. Review. Erratum in: Lancet 2002 Sep 14;360(9336):880.

PMID:
12020523
6.

Breastfeeding promotion and priority setting in health.

Horton S, Sanghvi T, Phillips M, Fiedler J, Perez-Escamilla R, Lutter C, Rivera A, Segall-Correa AM.

Health Policy Plan. 1996 Jun;11(2):156-68. Review.

7.

HIV prevention before HAART in sub-Saharan Africa.

Marseille E, Hofmann PB, Kahn JG.

Lancet. 2002 May 25;359(9320):1851-6. Review.

PMID:
12044394
8.

Assessment of the impact of cotrimoxazole prophylaxis on key outcomes among HIV-infected adults in low- and middle-income countries: a systematic review.

Saadani Hassani A, Marston BJ, Kaplan JE.

J Acquir Immune Defic Syndr. 2015 Apr 15;68 Suppl 3:S257-69. doi: 10.1097/QAI.0000000000000486. Review.

PMID:
25768865
9.

The economics, financing and implementation of HIV treatment as prevention: what will it take to get there?

Wilson D, Taaffe J, Fraser-Hurt N, Gorgens M.

Afr J AIDS Res. 2014;13(2):109-19. doi: 10.2989/16085906.2014.943254. Review.

PMID:
25174628
10.

HIV, tuberculosis, and noncommunicable diseases: what is known about the costs, effects, and cost-effectiveness of integrated care?

Hyle EP, Naidoo K, Su AE, El-Sadr WM, Freedberg KA.

J Acquir Immune Defic Syndr. 2014 Sep 1;67 Suppl 1:S87-95. doi: 10.1097/QAI.0000000000000254. Review.

PMID:
25117965
11.

The cost and cost-effectiveness of gender-responsive interventions for HIV: a systematic review.

Remme M, Siapka M, Vassall A, Heise L, Jacobi J, Ahumada C, Gay J, Watts C.

J Int AIDS Soc. 2014 Nov 4;17:19228. doi: 10.7448/IAS.17.1.19228. eCollection 2014. Review.

12.

The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic.

Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, Harrigan PR.

Lancet. 2006 Aug 5;368(9534):531-6. Review. No abstract available.

PMID:
16890841
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk